|
GB581334A
(en)
|
1943-09-29 |
1946-10-09 |
Francis Henry Swinden Curd |
New pyrimidine compounds
|
|
JPS4921149B1
(sr)
|
1970-12-28 |
1974-05-30 |
|
|
|
JPS4921148B1
(sr)
|
1970-12-28 |
1974-05-30 |
|
|
|
DE2341925A1
(de)
|
1973-08-20 |
1975-03-06 |
Thomae Gmbh Dr K |
Neue pyrimidinderivate und verfahren zu ihrer herstellung
|
|
AT340933B
(de)
|
1973-08-20 |
1978-01-10 |
Thomae Gmbh Dr K |
Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
|
|
US4994386A
(en)
|
1987-07-13 |
1991-02-19 |
Pharmacia Diagnostics, Inc. |
Production of HBLV virus in the HSB-2 cell line
|
|
US4929726A
(en)
|
1988-02-09 |
1990-05-29 |
Georgia State University Foundation, Inc. |
Novel diazines and their method of preparation
|
|
EP0330263A1
(en)
|
1988-02-25 |
1989-08-30 |
Merck & Co. Inc. |
Piperazinylalkylpyrimidines as hypoglycemic agents
|
|
GB9012311D0
(en)
|
1990-06-01 |
1990-07-18 |
Wellcome Found |
Pharmacologically active cns compounds
|
|
EP0489925B1
(en)
|
1990-07-03 |
1996-06-12 |
Mitsui Petrochemical Industries, Ltd. |
Pyrimidine compound and pharmaceutically acceptable salt thereof
|
|
EP0767170B1
(en)
|
1995-04-13 |
2002-10-23 |
Taiho Pharmaceutical Co., Ltd. |
Novel 4,6-diarylpyrimidine derivatives and salts thereof
|
|
JP3734907B2
(ja)
|
1996-12-19 |
2006-01-11 |
富士写真フイルム株式会社 |
現像処理方法
|
|
CA2297326C
(en)
|
1997-07-24 |
2007-03-20 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compound and antitumor agent containing the same as active component
|
|
JPH11158073A
(ja)
|
1997-09-26 |
1999-06-15 |
Takeda Chem Ind Ltd |
アデノシンａ３拮抗剤
|
|
US6440965B1
(en)
|
1997-10-15 |
2002-08-27 |
Krenitsky Pharmaceuticals, Inc. |
Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
|
|
US6150362A
(en)
|
1997-12-12 |
2000-11-21 |
Henkin; Jack |
Triazine angiogenesis inhibitors
|
|
PT930302E
(pt)
|
1998-01-16 |
2003-07-31 |
Hoffmann La Roche |
Derivados de benzo-sulfona
|
|
US7045519B2
(en)
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
ATE274510T1
(de)
|
1998-06-19 |
2004-09-15 |
Chiron Corp |
Glycogen synthase kinase 3 inhibitoren
|
|
US6495558B1
(en)
|
1999-01-22 |
2002-12-17 |
Amgen Inc. |
Kinase inhibitors
|
|
AU768201B2
(en)
|
1999-01-22 |
2003-12-04 |
Amgen, Inc. |
Kinase inhibitors
|
|
US6329380B1
(en)
|
1999-06-30 |
2001-12-11 |
Merck & Co., Inc. |
SRC kinase inhibitor compounds
|
|
ATE253915T1
(de)
|
1999-06-30 |
2003-11-15 |
Merck & Co Inc |
Src-kinase hemmende verbindungen
|
|
AU5889100A
(en)
|
1999-06-30 |
2001-01-31 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
|
JP2003505384A
(ja)
|
1999-07-15 |
2003-02-12 |
ファーマコピーア，インコーポレーティッド |
ブラジキニンｂ１受容体アンタゴニスト
|
|
JP2001089452A
(ja)
|
1999-09-22 |
2001-04-03 |
Sankyo Co Ltd |
ピリミジン誘導体
|
|
US20030004174A9
(en)
|
2000-02-17 |
2003-01-02 |
Armistead David M. |
Kinase inhibitors
|
|
HUP0300382A3
(en)
|
2000-03-29 |
2006-11-28 |
Cyclacel Ltd |
2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
|
|
WO2001083456A1
(fr)
|
2000-04-27 |
2001-11-08 |
Yamanouchi Pharmaceutical Co., Ltd. |
Derives d'heteroaryle condenses
|
|
NZ522217A
(en)
|
2000-04-28 |
2004-04-30 |
Tanabe Seiyaku Co |
Cyclic compounds
|
|
WO2002000647A1
(en)
|
2000-06-23 |
2002-01-03 |
Bristol-Myers Squibb Pharma Company |
Heteroaryl-phenyl substituted factor xa inhibitors
|
|
KR100816769B1
(ko)
|
2000-09-06 |
2008-03-26 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
글리코겐 합성효소 키나아제 3의 억제제
|
|
EP1317448B2
(en)
|
2000-09-15 |
2011-05-04 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
SE0004053D0
(sv)
|
2000-11-06 |
2000-11-06 |
Astrazeneca Ab |
N-type calcium channel antagonists for the treatment of pain
|
|
DE60120219T2
(de)
|
2000-12-21 |
2007-04-12 |
Vertex Pharmaceuticals Inc., Cambridge |
Pyrazolverbindungen als protein-kinase-inhibitoren
|
|
WO2002062766A2
(en)
|
2001-02-07 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Melanocortin-4 receptor binding compounds and methods of use thereof
|
|
WO2002064096A2
(en)
|
2001-02-16 |
2002-08-22 |
Tularik Inc. |
Methods of using pyrimidine-based antiviral agents
|
|
WO2002096876A1
(en)
|
2001-05-25 |
2002-12-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
|
JP2005500294A
(ja)
|
2001-06-19 |
2005-01-06 |
ブリストル−マイヤーズ スクイブ カンパニー |
ホスホジエステラーゼ７に対するピリミジン阻害剤
|
|
US6603000B2
(en)
|
2001-07-11 |
2003-08-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis for heteroarylamine compounds
|
|
WO2003030909A1
(en)
|
2001-09-25 |
2003-04-17 |
Bayer Pharmaceuticals Corporation |
2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
|
|
ATE468336T1
(de)
|
2002-03-15 |
2010-06-15 |
Vertex Pharma |
Azolylaminoazine als proteinkinasehemmer
|
|
EP1485376B1
(en)
|
2002-03-15 |
2007-06-27 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
US7091343B2
(en)
|
2002-03-15 |
2006-08-15 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
AU2003225800A1
(en)
|
2002-03-15 |
2003-09-29 |
Hayley Binch |
Azolylaminoazine as inhibitors of protein kinases
|
|
US20040082627A1
(en)
|
2002-06-21 |
2004-04-29 |
Darrow James W. |
Certain aromatic monocycles as kinase modulators
|
|
AU2003275242B2
(en)
|
2002-09-27 |
2010-03-04 |
Merck Sharp & Dohme Corp. |
Substituted pyrimidines
|
|
CA2501685A1
(en)
|
2002-10-08 |
2004-04-22 |
Massachusetts Institute Of Technology |
Compounds for modulation of cholesterol transport
|
|
US7223870B2
(en)
|
2002-11-01 |
2007-05-29 |
Pfizer Inc. |
Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
|
|
ATE527250T1
(de)
|
2002-11-21 |
2011-10-15 |
Novartis Ag |
2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs
|
|
CA2514733A1
(en)
|
2003-02-28 |
2004-09-16 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
|
US20060293339A1
(en)
|
2003-03-24 |
2006-12-28 |
Chakravarty Prasun K |
Biaryl substituted 6-membered heterocycles as sodium channel blockers
|
|
US20050014753A1
(en)
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
AU2004230928B2
(en)
|
2003-04-09 |
2010-12-02 |
Exelixis, Inc. |
Tie-2 modulators and methods of use
|
|
CA2531490A1
(en)
|
2003-07-15 |
2005-02-03 |
Neurogen Corporation |
Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands
|
|
EP1644358A2
(en)
|
2003-07-16 |
2006-04-12 |
Neurogen Corporation |
Biaryl piperazinyl-pyridine analogues
|
|
PE20050952A1
(es)
*
|
2003-09-24 |
2005-12-19 |
Novartis Ag |
Derivados de isoquinolina como inhibidores de b-raf
|
|
EP1742634B1
(en)
|
2004-04-13 |
2010-10-27 |
ICAgen, Inc. |
Polycyclic pyrimidines as potassium ion channel modulators
|
|
GB0415365D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415364D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
MY145822A
(en)
|
2004-08-13 |
2012-04-30 |
Neurogen Corp |
Substituted biaryl piperazinyl-pyridine analogues
|
|
EP1827434B1
(en)
*
|
2004-11-30 |
2014-01-15 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
|
JP2008523152A
(ja)
|
2004-12-13 |
2008-07-03 |
ニューロジェン・コーポレーション |
ピペラジニル−ピリジン類縁体
|
|
EP1824839A2
(en)
|
2004-12-13 |
2007-08-29 |
Neurogen Corporation |
Substituted biaryl analogues
|
|
CN101184734B
(zh)
|
2004-12-28 |
2013-05-29 |
金克斯医药品有限公司 |
治疗细胞增殖紊乱的化合物和方法
|
|
WO2006078992A2
(en)
|
2005-01-19 |
2006-07-27 |
Neurogen Corporation |
Heteroaryl substituted piperazinyl-pyridine analogues
|
|
AU2006217742A1
(en)
|
2005-02-25 |
2006-08-31 |
Kudos Pharmaceuticals Limited |
Hydrazinomethyl, HYDR zonomethyl and 5-membered heterocylic compounds which act as MTOR inhibitors and their use as anti cancer agents
|
|
AU2006236387A1
(en)
|
2005-04-18 |
2006-10-26 |
Neurogen Corporation |
Subtituted heteroaryl CB1 antagonists
|
|
GB2431156A
(en)
|
2005-10-11 |
2007-04-18 |
Piramed Ltd |
1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
|
|
KR20080083188A
(ko)
|
2006-01-11 |
2008-09-16 |
아스트라제네카 아베 |
모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
|
|
JO2660B1
(en)
*
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
EP2012794B1
(en)
*
|
2006-04-13 |
2014-09-17 |
The Trustees of Columbia University in the City of New York |
Compositions and intraluminal devices for inhibiting vascular stenosis
|
|
TW200833342A
(en)
|
2006-12-28 |
2008-08-16 |
Basf Ag |
2-substituted pyrimidines I in therapy
|
|
ES2381895T3
(es)
|
2007-02-06 |
2012-06-01 |
Novartis Ag |
Inhibidores de PI 3-quinasa y métodos para su uso
|
|
US7957951B2
(en)
|
2007-03-16 |
2011-06-07 |
Robert Bosch Gmbh |
Address translation system for use in a simulation environment
|
|
WO2009007748A2
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
|
WO2009066084A1
(en)
|
2007-11-21 |
2009-05-28 |
F. Hoffmann-La Roche Ag |
2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
|
|
WO2009109605A1
(en)
|
2008-03-05 |
2009-09-11 |
Novartis Ag |
Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
|
|
AU2009228797B2
(en)
|
2008-03-26 |
2012-07-19 |
Novartis Ag |
5imidazoquinolines and pyrimidine derivatives as potent modulators of VEGF-driven angiogenic processes
|
|
JP2011515462A
(ja)
|
2008-03-27 |
2011-05-19 |
アウククランド ウニセルビセス リミテッド |
置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用
|
|
WO2009125870A1
(en)
|
2008-04-09 |
2009-10-15 |
Mitsubishi Tanabe Pharma Corporation |
Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
|
|
GB0815369D0
(en)
|
2008-08-22 |
2008-10-01 |
Summit Corp Plc |
Compounds for treatment of duchenne muscular dystrophy
|
|
MX2011004585A
(es)
|
2008-10-31 |
2011-06-01 |
Novartis Ag |
Combinacion de un inhibidor de fosfatidilinositol-3-cinasa (p13k) y un inhibidor de mtor.
|
|
GB2465405A
(en)
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
|
WO2010068863A2
(en)
|
2008-12-12 |
2010-06-17 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Pyrimidine compounds and methods of making and using same
|
|
JP5747440B2
(ja)
|
2009-02-06 |
2015-07-15 |
住友化学株式会社 |
ヒドラジド化合物及びその有害生物防除用途
|
|
SI2394999T1
(sl)
|
2009-02-06 |
2014-05-30 |
Nippon Shinyaku Co., Ltd. |
Derivati aminopirazina in zdravilo
|
|
ES2740424T3
(es)
|
2009-03-13 |
2020-02-05 |
Agios Pharmaceuticals Inc |
Métodos y composiciones para trastornos relacionados con la proliferación celular
|
|
WO2010120994A2
(en)
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
|
|
DK2432767T3
(da)
|
2009-05-19 |
2013-09-30 |
Dow Agrosciences Llc |
Forbindelser og fremgangsmåder til at kontrollere svampe
|
|
EP2532659A1
(en)
|
2009-07-07 |
2012-12-12 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
US8609676B2
(en)
|
2009-08-04 |
2013-12-17 |
Merck Sharp & Dohme, Corp. |
4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
|
|
AR077999A1
(es)
|
2009-09-02 |
2011-10-05 |
Vifor Int Ag |
Antagonistas de pirimidin y triazin-hepcidina
|
|
AU2010292198A1
(en)
|
2009-09-09 |
2012-04-05 |
Celgene Avilomics Research, Inc. |
PI3 kinase inhibitors and uses thereof
|
|
EP2509600B1
(en)
|
2009-12-09 |
2017-08-02 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
|
|
GB201004200D0
(en)
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
|
WO2011133920A1
(en)
|
2010-04-23 |
2011-10-27 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
WO2011143160A2
(en)
|
2010-05-10 |
2011-11-17 |
The Johns Hopkins University |
Metabolic inhibitor against tumors having an idh mutation
|
|
JP6081354B2
(ja)
|
2010-07-16 |
2017-02-15 |
アジオス ファーマシューティカルズ， インコーポレイテッド |
治療活性組成物およびそれらの使用方法
|
|
CN104945373A
(zh)
|
2010-10-01 |
2015-09-30 |
诺华有限公司 |
制造嘧啶衍生物的方法
|
|
NZ718514A
(en)
|
2010-10-18 |
2017-10-27 |
Cerenis Therapeutics Holding Sa |
Compounds, compositions and methods useful for cholesterol mobilisation
|
|
GB201106829D0
(en)
|
2011-04-21 |
2011-06-01 |
Proximagen Ltd |
Heterocyclic compounds
|
|
RU2013141559A
(ru)
|
2011-02-11 |
2015-03-20 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Способ ингибирования клеток опухоли гамартомы
|
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
CN103764130A
(zh)
|
2011-09-01 |
2014-04-30 |
诺华股份有限公司 |
用于治疗骨癌或者预防原发性癌细胞转移性播散入骨中的pi3k抑制剂
|
|
PE20141581A1
(es)
|
2011-09-27 |
2014-11-14 |
Novartis Ag |
3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
|
|
US9365562B2
(en)
|
2011-10-06 |
2016-06-14 |
Merck Sharp & Dohme Corp. |
1,3 substituted azetidine PDE10 inhibitors
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
US10213432B2
(en)
*
|
2012-05-16 |
2019-02-26 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|
|
JP2015518888A
(ja)
|
2012-06-06 |
2015-07-06 |
ノバルティス アーゲー |
腫瘍疾患を治療するための１７−アルファ−ヒドロキシラーゼ（ｃ１７，２０−リアーゼ）インヒビターと特定のｐｉ−３ｋインヒビターとの組み合わせ
|
|
WO2014028566A1
(en)
|
2012-08-16 |
2014-02-20 |
Novartis Ag |
Combination of pi3k inhibitor and c-met inhibitor
|
|
BR112015007243B1
(pt)
|
2012-10-23 |
2022-02-08 |
Novartis Ag |
Processo aperfeiçoado para fabricação de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4- trifluorometilpiridin-2-amina
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
AU2014229283B2
(en)
|
2013-03-14 |
2016-07-28 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
|
|
CA2903979A1
(en)
|
2013-03-14 |
2014-09-18 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
CN103483345B
(zh)
|
2013-09-25 |
2016-07-06 |
中山大学 |
Pi3k激酶抑制剂、包含其的药物组合物及其应用
|
|
CN103694218B
(zh)
|
2013-12-05 |
2016-04-27 |
中山大学 |
嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用
|